Apollomics, Inc. (APLM)Healthcare | Biotechnology | Foster City, United States | NasdaqCM
21.77 USD
+0.60
(2.834%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:18 a.m. EDT
The immediate outlook is severely clouded by a collapse in share price and deteriorating liquidity. While the stock recently regained compliance with Nasdaq listing requirements, the market has punished the company heavily, with the price plunging over 21% recently and testing critical support levels. The technical picture is grim; the current price sits significantly below the 50-day average, indicating persistent selling pressure, and volume remains well below the daily average, suggesting a lack of active interest. For the long term, the investment case is fundamentally broken. The company is a biotech firm with no revenue growth to speak of, massive losses, and a negative book value, meaning shareholders have lost more than their initial investment. The price has been decimated over the last three years, dropping nearly 98% from its peak, reflecting a complete loss of market confidence in the business model. There is no dividend to provide any income cushion. While the recent recovery in listing status is a necessary administrative step, it does not alter the harsh reality that the underlying business is struggling to survive, making this a high-risk speculative vehicle rather than an investment opportunity. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.212791 |
| MSTL | 0.215469 |
| AutoTheta | 0.216287 |
| AutoETS | 0.216433 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 8.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.100 |
| Excess Kurtosis | -1.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 6.115 |
| Market Cap | 63,458,788 |
| Forward P/E | -33.49 |
| Beta | 1.54 |
| Profit Margins | -123.72% |
| Website | https://www.apollomicsinc.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3333333 |
| Address1 | 989 East Hillsdale Blvd. |
| Address2 | Suite 220 |
| All Time High | 4,900.0 |
| All Time Low | 3.659 |
| Ask | 21.89 |
| Ask Size | 6 |
| Average Daily Volume10 Day | 3,940 |
| Average Daily Volume3 Month | 16,706 |
| Average Volume | 16,706 |
| Average Volume10Days | 3,940 |
| Beta | 1.537 |
| Bid | 21.9 |
| Bid Size | 3 |
| Book Value | -1.485 |
| City | Foster City |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 21.77 |
| Current Ratio | 0.957 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 21.77 |
| Day Low | 21.77 |
| Display Name | Apollomics |
| Dividend Yield | 0.0 |
| Ebitda | -9,085,000 |
| Ebitda Margins | -1.02748 |
| Enterprise To Ebitda | -4.972 |
| Enterprise To Revenue | 5.109 |
| Enterprise Value | 45,175,052 |
| Eps Forward | -0.65 |
| Eps Trailing Twelve Months | -7.57 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 288 1674 |
| Fifty Day Average | 22.95856 |
| Fifty Day Average Change | -1.1885605 |
| Fifty Day Average Change Percent | -0.051769815 |
| Fifty Two Week Change Percent | -33.333332 |
| Fifty Two Week High | 40.015 |
| Fifty Two Week High Change | -18.244999 |
| Fifty Two Week High Change Percent | -0.455954 |
| Fifty Two Week Low | 10.006 |
| Fifty Two Week Low Change | 11.764001 |
| Fifty Two Week Low Change Percent | 1.1756947 |
| Fifty Two Week Range | 10.006 - 40.015 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,637,937,000,000 |
| Float Shares | 535,002 |
| Forward Eps | -0.65 |
| Forward P E | -33.49231 |
| Free Cashflow | -9,808,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Fullday Change | 0.6000004 |
| Fullday Change Percent | 2.834201 |
| Fullday Price | 21.77 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 8,842,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.56462 |
| Held Percent Institutions | 0.00423 |
| Implied Shares Outstanding | 2,914,965 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-03-30 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,732,492,800 |
| Last Split Factor | 1:100 |
| Long Business Summary | Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California. |
| Long Name | Apollomics, Inc. |
| Market | us_market |
| Market Cap | 63,458,788 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_382083491 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -10,939,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 68,210,181 |
| Open | 21.77 |
| Operating Cashflow | -10,369,000 |
| Operating Margins | 4.31871 |
| Phone | 650 209 4055 |
| Previous Close | 21.17 |
| Price Hint | 2 |
| Price To Book | -14.659933 |
| Price To Sales Trailing12 Months | 7.1769724 |
| Profit Margins | -1.2371601 |
| Quick Ratio | 0.911 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.6000004 |
| Regular Market Change Percent | 2.834201 |
| Regular Market Day High | 21.77 |
| Regular Market Day Low | 21.77 |
| Regular Market Day Range | 21.77 - 21.77 |
| Regular Market Open | 21.77 |
| Regular Market Previous Close | 21.17 |
| Regular Market Price | 21.77 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 2,034 |
| Return On Assets | -0.5761 |
| Return On Equity | -13.0536995 |
| Revenue Per Share | 6.115 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,914,965 |
| Shares Percent Shares Out | 0.002 |
| Shares Short | 5,730 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 7,413 |
| Short Name | Apollomics Inc. |
| Short Percent Of Float | 0.0031 |
| Short Ratio | 0.54 |
| Source Interval | 15 |
| State | CA |
| Symbol | APLM |
| Total Cash | 3,276,000 |
| Total Cash Per Share | 1.492 |
| Total Debt | 643,000 |
| Total Revenue | 8,842,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -7.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.9039 |
| Two Hundred Day Average Change | 2.8661003 |
| Two Hundred Day Average Change Percent | 0.15161423 |
| Type Disp | Equity |
| Volume | 2,034 |
| Website | https://www.apollomicsinc.com |
| Zip | 94,404 |